Loading...
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański, Radosław Hodgkinson, Cassandra L Fusi, Alberto Nonaka, Daisuke Priest, Lynsey Kelly, Paul Trapani, Francesca Bishop, P White, A Critchlow, S
Polański, Radosław
Hodgkinson, Cassandra L
Fusi, Alberto
Nonaka, Daisuke
Priest, Lynsey
Kelly, Paul
Trapani, Francesca
Bishop, P
White, A
Critchlow, S
Citations
Altmetric:
Abstract
The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use.
Description
Date
2014-02-15
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 1.02 MB
Keywords
Type
Article
Citation
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. 2014, 20 (4):926-37 Clin Cancer Res